Peter Siegel named Associate Director of the Rosalind and Morris Goodman Cancer Institute

The Rosalind & Morris Goodman Cancer Institute (GCI) is pleased to announce the appointment of Peter Siegel, PhD, as Associate Director, effective immediately. In this role, Professor Siegel will help guide the GCI’s strategic direction and support its mission to advance innovative cancer research, foster interdisciplinary collaboration, and translate scientific discoveries into improved outcomes for patients.

A Full Professor in McGill University’s Department of Medicine and longstanding member of the GCI, Professor Siegel is internationally recognized for his research on breast cancer, metastasis, and cancer metabolism.

As Associate Director, he will work closely with John Stagg, PhD, Director of the GCI, and the leadership team to advance key strategic priorities, including the development and implementation of the scientific strategy.

“We are delighted to welcome Peter into this leadership role,” said Director John Stagg. “His scientific expertise, collaborative spirit, and longstanding commitment to the GCI make him ideally suited to help advance our strategic vision.”

Professor Siegel obtained his PhD from McMaster University and completed a postdoctoral fellowship at Memorial Sloan Kettering Cancer Center. He joined McGill’s Department of Medicine as an Assistant Professor in 2004 and became a member of the GCI in 2007. Over the years, he has contributed extensively to the GCI’s scientific and operational activities, including serving as Interim Director (2012–2013) and Associate Director (2013–2018).

His research focuses on understanding how and why cancer spreads, examining the biological mechanisms that drive metastasis, how cancer cells adapt to and reshape new tissue environments, and how metabolic changes enable metastatic cells to survive and thrive. His work has been supported by numerous funding agencies, including the Terry Fox Research Institute, CIHR, FRQ, the Brain Tumour Foundation of Canada, the Canadian Cancer Society, and the Quebec Breast Cancer Foundation, among others.

Please join us in congratulating Professor Siegel on this appointment and wishing him continued success in this leadership role.